EARLY SCREEN · QUESTIONS TO TAKE TO AN RFI
How to qualify a biologics CDMO site
Use the reviewed public statements to frame a site-specific follow-up. This checklist does not certify a facility or replace sponsor qualification.
- Confirm molecule and host fit. Ask for modality, cell line/expression system, and site-specific molecule history at the exact US facility.
- Map the bioreactor train. Request vessel working volumes, stainless vs single-use trains, and scale-up paths; do not treat site totals or network claims as site-confirmed configurations.
- Check campaign timing and commercial scope. Request open campaign windows and lead times; installed capacity does not mean bookable slots, and early-phase sites may require separate commercial facilities.
- Review regulatory and GMP records. Obtain FDA Form 483 / Establishment Inspection Reports, applicable GMP certificates, and release/testing scope.
- Verify US supply-chain eligibility (editorial question). Applicability of sponsor procurement or BIOSECURE policies is unknown from vendor facility pages; confirm eligibility for your program directly.
- Compare commercial terms. Request batch pricing assumptions, tech-transfer fees, cancellation terms, and minimum commitments in writing.
Samsung Rockville supply-stage statements
The overview consolidates the following reviewed Samsung Biologics statements for Rockville:
- clinical-to-commercial biologics manufacturing — Source 1 ↗
- clinical and commercial supply — Source 2 ↗
- clinical and commercial biologics production (acquired from GSK March 31, 2026) — Source 3 ↗
← Return to the site comparison
See newly checked Seattle, Holly Springs and Costa Mesa site scope